U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601243) titled 'Study of GS-2426 in Participants With Advanced Solid Tumors' on May 15.
Brief Summary: The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.
The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced...